Send to

Choose Destination
Zhonghua Yi Xue Yi Chuan Xue Za Zhi. 2010 Feb;27(1):34-7. doi: 10.3760/cma.j.issn.1003-9406.2010.01.007.

[A clinical and laboratory study on acute myeloid leukemia with t(6;9)(p23;q34)].

[Article in Chinese]

Author information

Jiangsu Institute of Hematology, the First Affiliated Hospital of Soochow University, Thrombosis and Hemostasis Key Laboratory of the Ministry of Health, Soochow University, Suzhou, Jiangsu, 215006 P.R.China.



To explore the clinical and laboratory features of 6 cases of acute myeloid leukemia (AML) with t(6;9)(p23;q34).


Chromosome preparation of bone marrow cells was performed with regular method. R-banding by heating using Giemsa banding technique (RHG) was used for karyotype analysis. The immunoprofile was studied by flow cytometry (FCM) using a panel of monoclonal antibodies. Chromosome painting was performed by using whole chromosome paint probes for chromosomes 6 and 9 in all the 6 cases. The expression of fusion gene DEK/CAN and FLT3-ITD mutation were analyzed by reverse transcription-PCR(RT-PCR).


The t(6;9)(p23;q34) was found in all the 6 cases including 4 cases of M2 and 2 cases of M4. Blast cells were positive for CD13 and CD33 in 6 patients, for HLA-DR in 4 patients, for CD34 and CD117 in 3 cases, for CD38 or CD15 each in 1 case, respectively. A reciprocal translocation between chromosome 6 and 9 was confirmed by chromosome painting technique in the 6 cases. The DEK/CAN fusion gene was found in all the 6 cases, FLT3-ITD mutation was detected in three of them. Follow-up showed that 3 patients died with a survival time of 3 months, 5 months and 6 months, respectively. The other three obtained complete remission and are still alive.


The t(6;9)(p23;q34) is a rare recurrent abnormity. AML with t(6;9)(p23;q34) has unique clinical and laboratory features and its prognosis is poor in most cases.

[Indexed for MEDLINE]

Supplemental Content

Loading ...
Support Center